enGene Holdings Inc. (NASDAQ:ENGN) Stock Holdings Reduced by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP lowered its stake in shares of enGene Holdings Inc. (NASDAQ:ENGN) by 0.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,449,827 shares of the company’s stock after selling 11,523 shares during the period. enGene comprises 6.4% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 6th largest holding. Blue Owl Capital Holdings LP owned 5.55% of enGene worth $23,102,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently modified their holdings of the business. BVF Inc. IL purchased a new stake in shares of enGene in the fourth quarter valued at about $20,777,000. Logos Global Management LP lifted its holdings in shares of enGene by 50.0% in the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after purchasing an additional 400,000 shares in the last quarter. Omega Fund Management LLC purchased a new stake in shares of enGene in the fourth quarter valued at about $10,441,000. Janus Henderson Group PLC purchased a new stake in shares of enGene in the first quarter valued at about $17,095,000. Finally, SR One Capital Management LP purchased a new stake in shares of enGene in the second quarter valued at about $4,715,000. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Stock Performance

Shares of ENGN stock opened at $6.05 on Friday. enGene Holdings Inc. has a one year low of $4.42 and a one year high of $43.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. The company has a 50 day moving average price of $7.06 and a 200 day moving average price of $10.89. The firm has a market capitalization of $267.20 million, a price-to-earnings ratio of -3.65 and a beta of -0.68.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05. Sell-side analysts anticipate that enGene Holdings Inc. will post -1.64 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $40.00 price target on shares of enGene in a report on Wednesday, September 11th. Oppenheimer reissued an “outperform” rating and set a $30.00 price objective on shares of enGene in a research note on Tuesday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $33.67.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.